Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

NCT03808922 is registered in ClinicalTrials.gov with Ansun Biopharma, Inc. as lead sponsor.

NCT NCT03808922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03808922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Lead sponsor
Ansun Biopharma, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
May 23, 2019
Completion date
September 1, 2028
Enrollment
274 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, immunocompromised, lower respiratory tract infection, parainfluenza